ArticleJournal for immunotherapy of cancer2020
Article in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.Molecules (Basel, Switzerland) · 2021Pooled it
- Challenges in tracer development for tumor microenvironment (TME) imaging.European journal of nuclear medicine and molecular imaging · 2026Review
- Co-Formulation of Pembrolizumab Murine Surrogate RMP1-14 with ImagentPharmaceutics · 2026Article
- Fluorine-18-Labeled Nucleotide Analogs Targeting Ecto-5'-Nucleotidase (CD73) for Positron Emission Tomography Imaging of Solid Tumors.Angewandte Chemie (International ed. in English) · 2026Article
- ImmunoPET with Zirconium-89 specifically detects postoperative biofilm-associated implant infections: a preclinical study.EJNMMI research · 2026Article
- Hepatocellular Carcinoma Around the Clock.Current oncology (Toronto, Ont.) · 2026Review
- Immune remodeling during cervical cancer chemoradiotherapy: temporal biomarkers and the timing of checkpoint blockade.Frontiers in immunology · 2026Review
- FDG PET/CT in the post-treatment evaluation of breast cancer: an emphasis on triple-negative breast cancer.American journal of nuclear medicine and molecular imaging · 2026Review
- Pathogen-Specific Actinium-225 and Lutetium-177 Labeled Antibodies for Treatment of Biofilm-Associated Implant Infections:Antibiotics (Basel, Switzerland) · 2025Article
- 3'-deoxy-3'-EJNMMI research · 2025Article
- Validation of the C-X-C chemokine receptor 3 (CXCR3) as a target for PET imaging of T cell activation.EJNMMI research · 2024Article
- Animal model considerations for chordoma research: reproducing the tumor microenvironmentFrontiers in oncology · 2024Review
- New Long-Acting [Journal of medicinal chemistry · 2023Article
- Evaluation ofACS omega · 2023Article
- Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy.European journal of nuclear medicine and molecular imaging · 2023Review
- Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Immuno-PET imaging of PD-L1 expression in patient-derived lung cancer xenografts with [Quantitative imaging in medicine and surgery · 2022Article
- Immuno-Imaging (PET/SPECT)-Quo Vadis?Molecules (Basel, Switzerland) · 2022Review
- ImmunoPET: harnessing antibodies for imaging immune cells.Molecular imaging and biology · 2022Review
- Probing immune infiltration dynamics in cancer by in vivo imaging.Current opinion in chemical biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo better predict response to immune checkpoint therapy and toxicity in healthy tissues, insight in the in vivo behavior of immune checkpoint targeting monoclonal antibodies is essential. Therefore, we aimed to study in vivo pharmacokinetics and whole-body distribution of zirconium-89 (
methodsHumanized (huNOG) and non-humanized NOG mice were xenografted with human A375M melanoma cells. PET imaging was performed on day 7 post
resultsPET imaging and biodistribution studies showed high
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.